Contact WAO | e-News Sign Up | Site Map | Home  
World Allergy Organization
WAO's mission: To be a global resource and advocate in the field of allergy, advancing excellence in clinical care through education, research and training as a world-wide alliance of allergy and clinical immunology societies.

An Update on Severe Asthma

The Epidemiology of Severe Asthma: The TENOR Study and SARP (NIH)

Eugene R. Bleecker, MD
Thomas H. Davis Professor of Pulmonary Medicine
Section Head, Pulmonary, Critical Care, Allergy and Immunologic Diseases
Co-Director, Center for Human Genomics
Winston-Salem, NC USA

"Severe Asthma" consists of up to 20% of asthma patients who have frequent and severe symptoms despite aggressive therapy with anti-inflammatory as well as other controller medications. They often have fixed and progressive reductions in pulmonary function that do not reverse completely either after intense acute or long-term therapy. These abnormalities in lung function may reflect structural changes in the airways that have been classified as "airway remodeling". The varied clinical patterns found in severe asthma may reflect genetic differences that regulate bronchial inflammation and interact with environmental stimuli resulting in the characteristic pathophysiologic abnormalities as well as propensity to airway remodeling. In addition, pharmacogenetic responses may alter expected therapeutic responses and influence asthma severity. Thus, it is important to understand and characterize the clinical and inflammatory phenotyes in patients with severe asthma. Specific disease patterns may emerge during this comprehensive phenotype evaluation (including biomarkers), which would allow us to better understand the pathogenesis, development and treatment of more severe asthma.

The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimes (TENOR) study was a two to three year multi-center observational cohort study of asthmatics described as "difficult to treat" by their physicians, sponsored by Genentech and Novartis. It was not a clinical trial but rather a longitudinal cohort study of 4,756 patients (15% African American, 6.4% Hispanic, and 1.5% Asian or Pacific Islanders) with asthma aged 6 or older from 283 clinical centers including managed care, HMO, community and academic centers. Subjects were included if they had physician-characterized difficult-to-treat asthma, and met additional criteria based on frequency of urgent care visits and/or the use of multiple controller medications. In this group of asthmatics , 44.6% met the NHLBI National Asthma Education and Prevention Program (NAEPP) expert panel guidelines for severe persistent asthma, 27.5% for moderate persistent asthma, and 27.8% for mile persistent asthma. All subjects were evaluated initially with comprehensive questionnaires and laboratory testing, and were seen every 6 months during the remaining 2-3 years of the study. Detailed phenotypic information collected includes information on asthma exacerbations, medication use, urgent care visits, quality of life, pulmonary function tests (spirometry with reversibility), total serum IgE levels and history of allergies. Difficult-to-treat or severe asthma is common, representing a significant subset of asthmatics, estimated at 20% of patients with asthma. In addition, these severe asthmatics use disproportionately more healthcare resources.

The NIH (NHLBI) Severe Asthma Research Program (SARP) has characterized over 1000 asthmatics of varying severity (and ~200 normal controls), including over 400 subjects with severe asthma. All subjects underwent detailed clinical, physiologic, inflammatory and in a subset, radiologic phenotyping. In addition, DNA from all SARP subjects is being genotyped using the Illumina 1 million SNP ship for Genome Wide Associations Studies (GWAS) analysis as part of the NHLBI funded STAMPEED project. Investigative bronchoscopies are routinely performed as part of each of the independent SARP research projects.

While the NAEPP expert panel guidelines represent an important approach to classify asthma severity, the guidelines have well recognized problems which limit their use in clinical practice and clinical research. For example, the need to classify severity of patients when they are "off" medications is both impractical and, for the severe of difficult-to-treat asthmatic, can be dangerous. In addition, clinical investigators have recognized that asthmatics labeled "severe" can be characterized by several different clinical patterns of disease expression. In some patients, frequent and severe symptoms occur despite aggressive therapy with anti-inflammatory as well as other controller medications. Other patients with asthma have fixed and progressive reductions in pulmonary function that do not reverse completely either after intense acute or long-term therapy. These abnormalities in lung function may reflect structural changes in the airways that have been classified as "airway remodeling".

The varied clinical patterns found in difficult-to-treat and severe asthma almost certainly reflect genetic differences interacting with environmental factors that regulate bronchial inflammation resulting in characteristic pathophysiologic abnormalities, the propensity for airway remodeling, and different responses to asthma controller therapy. Pharmacogenetic responses may be particularly important in these patients since the more difficult-to-treat asthma patients may not respond as well to controller therapies as do other asthmatics. Thus, it is important to carefully define and characterize the phenotypic characteristics of difficult-to-treat and severe asthma in large population samples throughout the world.

References

  1. Borish L, Chipps B, Deniz Y, Gujrathi S, Zheng B, Dolan CM, for the TENOR Study Group. Total Serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. Annals of Allergy, Asthma & Immunology 2005:95;247-253.
  2. Brasier AR, Victor S, Boetticher GD, Ju H, Lee C, Bleecker ER, Castro M, Busse WW, Calhoun WJ. Molecular phenotyping of severe asthma: informative cytokine patterns in bronchoalveolar lavage. J Allergy Clin Immunol 2008; 121:30-37.
  3. Busse WW, Banks-Schlegel S, Wenzel SE. Pathophysiology of severe asthma. J Allergy Clin Immunol 2000:106(6):1033-1042.

  4. Chen H, Blanc PD, Hayden ML, Bleecker ER, Chawla A, Lee JH, for the TENOR Study Group. Assessing Productivity Loss and Activity Impairment in Severe or Difficult-to Treat Asthma. Value in Health 2008:11;231-239.
  5. Chipps BE, Szefler SJ, Simons ER, Haselkorn T, Mink DR, Deniz Y, Lee J, for the TENOR Study Group. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allerghy Clin Immunol 2007:119;1156-1163.
  6. Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML, Weiss S, Zheng B, Johnson D, Wenzel S, for the TENOR Study Group. Design and baseline characteristics of the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study-a large cohort of patients with severe or difficult-to-treat-asthma. Annals of Allergy, Asthma & Immunology 2004; 92:32-39.
  7. ENFUSOMA Study Group. The Enfusoma cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003:22:470-7.
  8. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of a subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002:57:875-9.
  9. Mascia K, Haselkorn T, Deniz Y, Mangeshkar M, Bleecker ER, Borish L. Aspirin sensitivity and severity of asthma: Evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005; 116:970-975.
  10. Moore WC, Bleecker ER, Curran-Everett, Erzurum SC, Ameredes BT, Bacharier L, Calhoun WJ, Castro M, Chung KF, Clark MP, Dweik RA, Fitzpatrick AM, Gaston B, Hew M, Hussain I, Jarjour NN, Israel E, Levy BD, Murphy JR, Peters SP, Teague WG, Meyers DA, Busse WW, Wenzel SE, for the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007:119;405-413.
  11. Sorkness RL, Bleecker ER, Busse EE, Calhoun WJ, Castor M, Chung KF, Curran-Everett D, Erzurum SC, Gaston BM, Israel E, Jarjour NN, Moore WC, Peters SP, Teague WG, Wenzel SE for the National Heart, Lung, Blood Institute Severe Asthma Research Program. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physoil 2008;104: 394-403.
  12. Sullivan SD, Rasouliyan L, Russo, Kamath T, Chipps BE, for the TENOR Study Group. Allergy 2007:62;126-133.
  13. Sullivan SD, Wenzel SE, Bresnahan BW, Zheng B, Lee JH, Pritchard M, Kamath TV, Weiss ST, for the TENOR Study. Association of control and risk of sever asthma-related events in sever or difficult-to-treat asthma patients. Allergy 2007:62;655-660.
  14. Wenzel SE. Severe Asthma in adults. AM J Respir Crit Care Med 2005: 172:149-160.
  15. Wenzel SE, Fahy JV, Irvin C, Peters SP, Spector S, Szefler S. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. AM J Respir Crit Care Med 2000.162:2341-51.
  16. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. AM J Respir Crit Care Med 1999: 160;1001-1008.
  17. Wenzel SE, Balzar S, Ampleford EJ, Hawkins GA, Busse WW, Calhoun WJ, Castro M, Chung KF, Erzurum S, Gaston B, Israel E, Teague EG, Meyers DA, Bleecker ER. Il-4R? Mutations are associated with asthma exacerbations, airway obstruction, tissue mast cells/IgE expression and racial background. Amer J Resp Crit Care Med 2007; 175:570-576.

Slide presentation

Return to top
Return to WAF: Barcelona, Spain index